Latanoprostene bunod ophthalmic solution

(Vyzulta®)

Latanoprostene bunod ophthalmic solution

Drug updated on 11/14/2023

Dosage Formsolution (topical ophthalmic: 0.24 mg/mL (0.024%))
Drug ClassProstaglandin analogs
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Product Monograph / Prescribing Information

Document TitleYearSource
Vyzulta (latanoprostene bunod ophthalmic solution) Prescribing Information.2019Bausch Health US, LLC, Bridgewater, NJ

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines

Document TitleYearSource
Primary open-angle glaucoma PPP 2020.2020American Academy of Ophthalmology